

Asst. Prof. BAŐAK ELTİKİ

Personal Information

Email: bceltics@hacettepe.edu.tr

Web: https://avesis.hacettepe.edu.tr/bceltics

Biography

Ö Ğ R E N İ M

MCGILL ÜNİVERSİTESİ, MONTREAL, KANADA

Ocak 2003 – Mayıs 2008

Tıp Fakültesi

İnsan Genetiđi Bölümü

Doktora öğrenimi (Danışmanı: Prof. Dr. Rima Rozen)

Tez konusu: Metilentetrahidrofolat reduktazın faredeki farklı ekspresyonun metotreksat ve 5-flurourasil tedavilerinde cevaba etkisi.

HACETTEPE ÜNİVERSİTESİ, ANKARA, TÜRKİYE

Tıp Fakültesi

Biyokimya ve Klinik Biyokimya Anabilim Dalı

Klinik Biyokimya uzmanlık eğitimi (Danışmanı: Prof. Dr. Asuman Ozkara)

Haziran 2000 – Aralık 2009

Tez konusu: GM1 gangliozidoz ve Fabry hastalıklarında hatalı enzimlerdeki mutasyonların pcr-sscp ve DNA dizi analizi ile belirlenmesi

Eylül 1993 – Haziran 1999

ANKARA ÜNİVERSİTESİ, ANKARA, TÜRKİYE

Tıp Fakültesi

Tıp Doktorluğu eğitimi

CGPA: 83.12/100 (99 dönemi üçüncüsü)

Eylül 1982 – Haziran 1993

TED ANKARA KOLEJİ, ANKARA, TÜRKİYE

İlk-orta-lise eğitimi

Education Information

Post Doctorate, Mayo Clinic, Tıp Fakültesi, Kanser Enstitüsü, United States Of America 2016 - 2017

Post Doctorate, University of Minnesota, Tıp Fakültesi, Kanser Enstitüsü, United States Of America 2015 - 2016

Post Doctorate, The Queen's University of Belfast, Tıp Fakültesi, Kanser Enstitüsü, England 2013 - 2015

Expertise In Medicine, Hacettepe University, Tıp Fakültesi (Türkçe), Temel Tıp Bilimleri Bölümü, Turkey 2000 - 2009

Doctorate, McGill University, Tıp Fakültesi, Genetik, Canada 2003 - 2008

Under Graduate, Ankara University, School Of Medicine, Turkey 1993 - 1999

Foreign Languages

English, C2 Mastery

Dissertations

Expertise In Medicine, GM1 Gangliozidoz ve Fabry hastalıklarında hatalı enzimlerdeki mutasyonların PCR-SSCP ve DNA dizi analizi ile belirlenmesi, Hacettepe University, Tıp Fakültesi (Türkçe), Temel Tıp Bilimleri Bölümü, 2009

Doctorate, Altered expression of methylenetetrahydrofolate reductase modifies response to methotrexate and 5-fluorouracil in mice, McGill University, Tıp Fakültesi, Genetik, 2008

Research Areas

Health Sciences

Academic Titles / Tasks

Assistant Professor, Hacettepe University, Tıp Fakültesi (Türkçe), Temel Tıp Bilimleri Bölümü, 2019 - Continues

Assistant Professor, Ufuk University, School Of Medicine, Department Of Internal Medicine, 2017 - 2019

Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- I. **A Crosstalk Between Dual-Specific Phosphatases and Dual-Specific Protein Kinases Can Be A Potential Therapeutic Target for Anti-cancer Therapy.**
Celtikci B.
Advances in experimental medicine and biology, vol.1275, pp.357-382, 2021 (Journal Indexed in SCI)
- II. **Regulation And Effect Of Telomerase And Telomeric Length In Stem Cells.**
Celtikci B., Erkmn G. K. , Dikmen Z. G.
Current stem cell research & therapy, vol.16, pp.809-823, 2021 (Journal Indexed in SCI)
- III. **HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL**
Carson R., ÇELTİKÇİ B., Fenning C., Javadi A., Crawford N., Perez-Carbonell L., Lawler M., Longley D. B. , Johnston P. G. , Van Schaeybroeck S.
CLINICAL CANCER RESEARCH, vol.21, no.14, pp.3230-3240, 2015 (Journal Indexed in SCI)
- IV. **Four novel mutations in the beta-galactosidase gene identified in infantile type of GM1 gangliosidosis**
CELTIKCI B., AYDIN H. I. , Sivri S., Sonmez M., TOPÇU M., ÖZKARA H. A.
CLINICAL BIOCHEMISTRY, vol.45, pp.571-574, 2012 (Journal Indexed in SCI)
- V. **Two novel alpha-galactosidase A mutations causing Fabry disease: A missense mutation M11V in a heterozygote woman and a nonsense mutation R190X in a hemizygote man.**
CELTIKCI B., TOPÇU M., ÖZKARA H. A.
Clinical biochemistry, vol.44, pp.809-12, 2011 (Journal Indexed in SCI Expanded)
- VI. **Establishment of Green Fluorescent Protein Expressing CHO Cells by Stable Transfection Using Activated Dendrimers and G418 Selection**
CELTIKCI B., PURALI N., ÖZKARA H. A.
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, vol.35, no.4, pp.340-343, 2010 (Journal Indexed in SCI)
- VII. **Methotrexate-induced apoptosis is enhanced by altered expression of methylenetetrahydrofolate reductase**
ÇELTİKÇİ B., Lawrance A. K. , Wu Q., Rozen R.
ANTI-CANCER DRUGS, vol.20, no.9, pp.787-793, 2009 (Journal Indexed in SCI)
- VIII. **Protective role of 27bp repeat polymorphism in intron 4 of eNOS gene in lacunar infarction**
Yemisci M., Sinici I., ÖZKARA H. A. , Hayran M., AY H., CELTIKCI B., ONDER E., Buyukserbetci G., Kaya E. B. , Tokgozoglu L., et al.
FREE RADICAL RESEARCH, vol.43, no.3, pp.272-279, 2009 (Journal Indexed in SCI)
- IX. **Increased hexosaminidase activity in antipsychotic-induced extrapyramidal side effects: Possible association with higher occurrence in bipolar disorder patients**
Tunca Z., RESMI H., ÖZKARA H. A. , Ciliz G., CELTIKCI B., ALPTEKIN K., OZERDEM A., AKDEDE B. K. , BAYKARA B., BIRSOY B., et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol.32, no.5, pp.1214-1220, 2008 (Journal Indexed in SCI)
- X. **Altered expression of methylenetetrahydrofolate reductase modifies response to methotrexate in mice**
ÇELTİKÇİ B., Leclerc D., Lawrance A. K. , Deng L., Friedman H. C. , Krupenko N. I. , Krupenko S. A. , Melnyk S., James S. J. , Peterson A. C. , et al.
PHARMACOGENETICS AND GENOMICS, vol.18, no.7, pp.577-589, 2008 (Journal Indexed in SCI)

Refereed Congress / Symposium Publications in Proceedings

- I. **Two forms of a disease in the same family: compound heterozygosity in the father and his sister both with corneal cystinosis, and heterozygous daughter and his other sister both having risks for nephropathic cystinosis**
ÇELTİKÇİ B., Kazancı B.
European Human Genetics Virtual Conference, Berlin, Germany, 06 June 2020
- II. **Two families having Huntington'x's disease with two different clinical presentations**
ÇELTİKÇİ B., Kaplan F., SAYIN R.
EUROPEAN HUMAN GENETICS CONFERENCE, Gothenburg, Sweden, 15 - 18 June 2019, vol.27, pp.1865
- III. **The effects of human chorionic gonadotropin-based hormonal therapy on the expression levels of proliferating cell nuclear antigen**
ÇELTİKÇİ B., TANGAL S., ÖZER L.
13. Balkan Congress of Human Genetics, 17 - 20 April 2019
- IV. **The role of JAK1/2-STAT3 as acute resistance mechanism to MEK inhibition in BRAF-mutant colorectal cancer cell lines.**
ÇELTİKÇİ B., Carson R., Johnston P. G. , Van Schaeybroeck S.
JOURNAL OF CLINICAL ONCOLOGY, Chicago, 30 May - 03 June 2014, vol.32
- V. **The role of JAK1/2-STAT3 as acute resistance mechanism to MEK inhibition in BRAF mutant colorectal cancer**
Carson R., ÇELTİKÇİ B., Johnston P. G. , Van Schaeybroeck S., Dunne P.
MOLECULAR CANCER THERAPEUTICS, 10 - 13 November 2013, vol.12
- VI. **The establishment of Green Fluorescent Protein expressing CHO cells by stable transfection using activated dendrimers and G418 selection**
ÇELTİKÇİ B., ÖZKARA H. A. , PURALI N.
FEBS JOURNAL, Prague, 4 - 09 July 2009, vol.276, pp.215-216
- VII. **Increased hexosaminidase activity in psychiatric patients with drug induced extrapyramidal side effects**
Tunca Z., Resmi H., Ozkara A., Ciliv G., Celtikci B., Alptekin K., Ozerdem A., Akdede B., Baykara B., Birsoy B., et al.
62nd Annual Scientific Meeting of the Society-of-Biological-Psychiatry, California, United States Of America, 01 January 2007, vol.61
- VIII. **Protective role of 27 bp deletion polymorphism in intron 4 of eNOS gene in cerebral small-vessel disease**
Yemisci M., Sinici I., ÖZKARA H. A. , HAYRAN K. M. , ay h., ÇELTİKÇİ B., Onder E., DALKARA T.
FEBS JOURNAL, İstanbul, Turkey, 24 - 29 June 2006

Citations

Total Citations (WOS):103

h-index (WOS):5